 -Study May Proceed Letter Received from FDA Under Investigator IND- -EBRIS plans to initiate Phase 2a trial in MIS-C in Q4 2021 at Massachusetts General Hospital for Children- -Translational evidence reported previously in Journal of Clinical Investigation detailing larazotides mechanism in addressing MIS-C- RALEIGH, NC ACCESSWIRE August 16, 2021 9 Meters Biopharma, Inc. NASDAQ:NMTR the Company, a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, today announced a collaboration with the European Biomedical Research Institute of Salerno, Italy EBRIS to study larazotide for the treatment of multisystem inflammatory syndrome in children MIS-C. Larazotide is a novel first-in-class tight junction regulator that the Company currently has in Phase 3 clinical development for adults with celiac disease. 